Orthocell jumps as nerve repair tech shows hope for erectile dysfunction post-prostate surgery
Orthocell shares popped +10% as the company reported its flagship nerve repair product, Remplir, is being used by Australian urologists.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
KSO | Announcements released on 5 Feb 2016 as XF1 | 06/02/16 | 0 | 1.2K | |||
|
|||||||
KSO | XF1 - Feb 5 2016 | 05/02/16 | 5 | 3.9K | |||
|
|||||||
KSO | Ann: Replacement Prospectus | 04/02/16 | 67 | 30K | |||
|
|||||||
KSO | XREF Listing Date | 03/02/16 | 0 | 1.0K | |||
|
|||||||
KSO | Ann: Appendix 3B Issue of Options | 01/02/16 | 0 | 886 | |||
|
|||||||
KSO | New sales of Xref credits in excess of 100% on an annualised basis | 31/01/16 | 0 | 1.1K | |||
|
|||||||
KSO | Ann: Quarterly Activities Report | 29/01/16 | 0 | 890 | |||
|
|||||||
KSO | Ann: Quarterly Cashflow Report | 29/01/16 | 0 | 723 | |||
|
See All Discussions